BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

  The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

  September 14, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  As Impact of Substance Use Disorders Rise, So Do Innovative Solutions

  From reversing overdose to blocking cravings, the biopharma industry is looking at a range of possible solutions to addiction.

  September 14, 2023

   · 

  4 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  African Green Monkeys Play Key Role in Advancing Preclinical Research Amid Supply Chain Shortage

  As researchers face delayed project timelines and inflated costs, industry leaders are offering an alternative option for sourcing nonhuman primates.

  September 14, 2023

   · 

  5 min read

   · 

  BioSpace Insights
• 

  Business

  New Biotech Targets Rare Respiratory Disorders with Inhaled Gene Therapies

  AlveoGene has licensed the U.K. Respiratory Gene Therapy Consortium’s InGenuiTy platform for all uses excluding the CTFR gene, which is already licensed to Boehringer Ingelheim for cystic fibrosis.

  September 14, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Generate Raises $273M in Series C Financing with New Investors Amgen, NVIDIA

  In the largest biotech Series C financing so far this year, Generate:Biomedicines picked up new investors including Amgen and NVIDIA’s venture capital arm to advance its pipeline of 17 programs.

  September 14, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Moderna Axes Four Clinical Development Programs, Two AstraZeneca Had Dropped

  During Wednesday’s annual R&D Day, Moderna said it is culling four programs from its pipeline, including two molecules that had been discontinued last year by AstraZeneca.

  September 14, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  6 Key Regulatory Guidance Documents Issued in 2023

  The FDA has issued more than 30 guidance documents related to drug development so far this year. BioSpace takes a closer look at six of them.

  September 14, 2023

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Drug Development

  BMS Culls Two Mid-Stage, Four Early-Stage Clinical Programs

  Bristol Myers Squibb’s pipeline cuts, announced Thursday during its R&D Day, include a mid-stage drug candidate for nonalcoholic steatohepatitis and an anti-TIGIT solid tumor program.

  September 14, 2023

   · 

  3 min read

   · 

  Connor Lynch
• Genetown

  Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene

  Nona Biosciences announced an agreement with BeiGene, Ltd. to expand the companies’ discovery strategic collaboration leveraging Nona’s proprietary Harbour Mice® platform.

  September 14, 2023

   · 

  2 min read
• Business

  CancerVAX CEO Ryan Davies Discusses the Company’s Growing Pipeline of Cancer Treatments

  CancerVAX, Inc. announced that in a recent podcast its CEO, Ryan Davies, spoke about the Company’s growing pipeline of cancer treatments under development at UCLA.

  September 14, 2023

   · 

  3 min read